



Liquidity contract's first half review entrusted to the investment company Bryan, Garnier & Co.

Lyon (France), 08 July 2013—ERYTECH (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical need, announces today it liquidity contract's first half review entrusted to the investment company Bryan, Garnier & Co.

Under the liquidity contract entrusted to Bryan, Garnier & Co, concerning ERYTECH's shares, the liquidity account held the following assets on 30 June 2013:

- 52 890 ERYTECH's shares
- 1 953,88 euros in cash.

It should be noted that during the contract implementation, the following assets have been brought to the liquidity account:

- 0 ERYTECH's shares
- 600 000 euros in cash.

About ERYTECH: www.erytech.com

Created in Lyon in 2004, ERYTECH is a French biopharmaceuticals company that opens new prospects for cancer patients, particularly those with acute leukaemia. By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed GRASPA[®], an original and effective treatment that targets cancer cells through "starvation" while significantly reducing the side effects for patients. GRASPA[®] is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML). ERYTECH has concluded distribution partnership agreements for Europe with Orphan Europe (Recordati group), and with TEVA for Israël. In the United States, ERYTECH is launching a Phase Ib clinical trial in ALL, after having received approval from the US FDA. The company has its own GMP approved and operational manufacturing site.

ERYTECH is listed on NYSE Euronext regulated market in Paris. (Code ISIN : FR0011471135, mnémo : ERYP) and is part of CAC Healthcare, CAC Pharm. & Bio et Next Biotech indexes.

CONTACTS

ERYTECH

Gil Beyen

Chairman and CEO

Pierre-Olivier Goineau

NewCap.

Investor and press relations

Julien Perez / Emmanuel Huynh

Tél : 01 44 71 98 52



Vice-President and COO

erytech@newcap.fr

Tel : 04 78 74 44 38

Fax : 04 78 75 56 29

investors@erytech.com